Research
Hormonal
The accumulation of senescent cells contributes to inflammaging through the Senescence-Associated Secretory Phenotype (SASP), which releases pro-inflammatory cytokines and chemokines.
Senescent cells, which are 'zombie' cells that stop dividing but don't die, secrete inflammatory signals (SASP) that damage surrounding tissue and drive chronic inflammation. This process is a major driver of age-related decline.
GoodSupportsHIGH confidence
Another hallmark of senescent cells is the acquisition of a senescence-associated secretory phenotype (SASP), which entails the chronic transcriptional induction and secretion of numerous pro-inflammatory cytokines, chemokines, growth factors and proteases.
Why this rating
Supported by multiple citations of mouse models and human tissue studies.
Source
Aging of the immune system: Focus on inflammation and vaccination
Marcello Pinti et al. · European Journal of Immunology · 2016
DOI 10.1002/eji.201546178
narrative_reviewCited 443×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Aging causes a chronic, low-grade inflammatory state (inflammaging) driven by senescent cells and immune dysregulation, which impairs vaccine efficacy and increases susceptibility to infection.Good
- Thymic involution with age leads to a reduced output of naive T cells, resulting in a narrowed T-cell receptor repertoire and impaired ability to mount new immune responses to novel antigens.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →